Clinical Trials
23 trialsNCT06295731 2026-05-08
HexAgon-HN
Inhibrx Biosciences, Inc
Phase 2/3 Active not recruiting
NCT07124000 2026-05-01
DP-04
AstraZeneca
Recruiting
NCT05461430 2026-04-13
TraveraRTGx
Travera Inc
Completed
NCT06736379 2026-01-20
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
VLP Therapeutics
Phase 1 Recruiting
NCT05312710 2026-01-16
Safety and Efficacy of APG-157 in Head and Neck Cancer
Aveta Biomics, Inc.
Phase 2 Active not recruiting
NCT04198766 2025-12-18
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Phase 1/2 Active not recruiting
NCT03589339 2025-10-24
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Nanobiotix
Phase 1 Active not recruiting
NCT05451303 2025-01-29
Detection of Oral and Throat Cancers Using OralViome Cancer Testing System
Viome
Recruiting
NCT06174428 2025-01-29
Validity of Viome's Oral/throat Cancer Test
Viome
Recruiting
NCT04985357 2024-11-25
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Withdrawn
NCT05966194 2024-11-15
KEVLARx
EpicentRx, Inc.
Phase 2 Recruiting
NCT04622462 2024-11-07
Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment
Proteocyte Diagnostics Inc.
Recruiting
NCT03515538 2024-11-04
PREVLAR
EpicentRx, Inc.
Phase 2 Completed
NCT03329950 2024-03-28
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
Phase 1 Completed
NCT03602079 2023-08-03
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
Phase 1/2 Completed
NCT03254927 2023-04-03
A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Celldex Therapeutics
Phase 2 Terminated
NCT01946867 2022-12-29
NBTXR3 and Radiation Therapy in Treating Patients With Locally Advanced SCC of the Oral Cavity or Oropharynx
Nanobiotix
Phase NA Unknown
NCT05049408 2021-09-28
Verification of Saliva MMP-1 as a Diagnostic Marker of Oral Cavity Cancer
S&T Biomed Co., Ltd.
Completed
NCT00210470 2020-12-11
A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer
Brooklyn ImmunoTherapeutics, LLC
Phase 2 Completed
NCT00272181 2015-12-23
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
Sesen Bio, Inc.
Phase 2 Terminated
NCT00412776 2015-12-23
Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer
Sesen Bio, Inc.
Phase 2/3 Terminated
NCT00413322 2015-07-08
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
Valerio Therapeutics
Phase 1 Completed
NCT00028405 2005-06-24
Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors
Light Sciences LLC
Phase 1 Completed